MX343114B - Anticuerpos contra la tweak humana y usos de los mismos. - Google Patents
Anticuerpos contra la tweak humana y usos de los mismos.Info
- Publication number
- MX343114B MX343114B MX2013003592A MX2013003592A MX343114B MX 343114 B MX343114 B MX 343114B MX 2013003592 A MX2013003592 A MX 2013003592A MX 2013003592 A MX2013003592 A MX 2013003592A MX 343114 B MX343114 B MX 343114B
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- tweak
- antibodies against
- against human
- human tweak
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
La presente invención se refiere a un anticuerpo que se fija sobre la TWEAK y se caracteriza porque como dominio variable de cadena larga contiene una CDR3H elegida entre el grupo formado por las SEC ID NO: 8, 16 ó 24 es útil para el tratamiento del cáncer o de enfermedades autoinmunes, artritis reumatoide, artritis psoriática, enfermedades musculares, por ejemplo, distrofia muscular, esclerosis múltiple, enfermedades renales crónicas, enfermedades óseas, por ejemplo, degeneración ósea en el mieloma múltiple, lupus eritematoso sistémico, nefritis por lupus y las lesiones vasculares.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10186536 | 2010-10-05 | ||
PCT/EP2011/067070 WO2012045671A1 (en) | 2010-10-05 | 2011-09-30 | Antibodies against human tweak and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013003592A MX2013003592A (es) | 2013-05-31 |
MX343114B true MX343114B (es) | 2016-10-25 |
Family
ID=43086385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013003592A MX343114B (es) | 2010-10-05 | 2011-09-30 | Anticuerpos contra la tweak humana y usos de los mismos. |
Country Status (21)
Country | Link |
---|---|
US (1) | US9187564B2 (es) |
EP (1) | EP2625200A1 (es) |
JP (1) | JP5941049B2 (es) |
KR (1) | KR101584416B1 (es) |
CN (1) | CN103154029B (es) |
AR (1) | AR083336A1 (es) |
AU (1) | AU2011311673B2 (es) |
BR (1) | BR112013007293A2 (es) |
CA (1) | CA2809632A1 (es) |
CL (1) | CL2013000901A1 (es) |
CR (1) | CR20130108A (es) |
EA (1) | EA201300418A1 (es) |
EC (1) | ECSP13012542A (es) |
HK (1) | HK1186195A1 (es) |
MA (1) | MA34642B1 (es) |
MX (1) | MX343114B (es) |
NZ (1) | NZ607588A (es) |
PE (1) | PE20131411A1 (es) |
SG (1) | SG188605A1 (es) |
TW (1) | TWI482630B (es) |
WO (1) | WO2012045671A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1387538A (zh) * | 1999-01-15 | 2002-12-25 | 比奥根公司 | 针对tweak及tweak受体的拮抗剂和它们在治疗免疫性疾病中的应用 |
CN103536916B (zh) | 2002-04-09 | 2016-08-17 | 比奥根Ma公司 | 用于治疗tweak相关病症的方法 |
EP1859277A4 (en) | 2005-02-17 | 2010-03-17 | Biogen Idec Inc | TREATMENT OF NEUROLOGICAL DISORDERS |
CA2607697C (en) | 2005-05-10 | 2015-01-06 | Biogen Idec Ma Inc. | Treating and evaluating inflammatory disorders |
WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
BR112013019975A2 (pt) | 2011-02-28 | 2017-08-01 | Hoffmann La Roche | proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira" |
EP2681240B1 (en) | 2011-02-28 | 2017-08-16 | F. Hoffmann-La Roche AG | Monovalent antigen binding proteins |
KR101674784B1 (ko) * | 2012-04-05 | 2016-11-09 | 에프. 호프만-라 로슈 아게 | 인간 tweak 및 인간 il17에 대한 이중특이적 항체 및 이의 용도 |
JP2016000003A (ja) * | 2013-04-19 | 2016-01-07 | アステラス製薬株式会社 | 新規抗ヒトtweak抗体 |
WO2015051234A2 (en) * | 2013-10-04 | 2015-04-09 | Biogen Idec Ma Inc. | Tweak antagonists for treating lupus nephritis and muscle atrophy |
WO2016016299A1 (en) * | 2014-07-29 | 2016-02-04 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
CN112180100A (zh) * | 2020-09-27 | 2021-01-05 | 西安交通大学 | Tweak作为鉴别不同类型银屑病的分子标志物的应用 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
JP3537535B2 (ja) | 1994-07-14 | 2004-06-14 | 株式会社中埜酢店 | 免疫グロブリンg結合糖鎖構造に基づく臨床検査方法 |
AU7668696A (en) | 1995-11-03 | 1997-05-22 | Austin Research Institute, The | Methods and compositions for the reduction of xenotransplantation rejection |
EP0956351B1 (en) | 1996-08-07 | 2005-10-19 | Biogen Idec MA Inc. | A tumor necrosis factor related ligand |
WO1998033523A1 (en) | 1997-01-31 | 1998-08-06 | Biovation Limited | Vaccination methods and molecules |
DE69833755T2 (de) | 1997-05-21 | 2006-12-28 | Biovation Ltd. | Verfahren zur herstellung von nicht-immunogenen proteinen |
PT1308456E (pt) | 1998-05-06 | 2007-12-03 | Genentech Inc | Purificação de anticorpos por cromatografia de permuta iónica |
AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
CN1387538A (zh) * | 1999-01-15 | 2002-12-25 | 比奥根公司 | 针对tweak及tweak受体的拮抗剂和它们在治疗免疫性疾病中的应用 |
CN103536916B (zh) | 2002-04-09 | 2016-08-17 | 比奥根Ma公司 | 用于治疗tweak相关病症的方法 |
RU2005141512A (ru) | 2003-05-31 | 2007-07-20 | Микромет Аг (De) | Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками |
WO2005012493A2 (en) | 2003-07-31 | 2005-02-10 | Immunomedics, Inc. | Anti-cd19 antibodies |
AR045614A1 (es) | 2003-09-10 | 2005-11-02 | Hoffmann La Roche | Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos |
WO2006052926A2 (en) | 2004-11-08 | 2006-05-18 | University Of Maryland, Baltimore | Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and and cell death |
AU2006214121B9 (en) | 2005-02-15 | 2013-02-14 | Duke University | Anti-CD19 antibodies and uses in oncology |
US20090068102A1 (en) | 2005-02-17 | 2009-03-12 | Biogen Idec Ma Inc. | Treating stroke |
EP1859277A4 (en) | 2005-02-17 | 2010-03-17 | Biogen Idec Inc | TREATMENT OF NEUROLOGICAL DISORDERS |
EP1853312B1 (en) * | 2005-03-07 | 2014-12-10 | Genentech, Inc. | Methods and compositions for modulating tweak and fn14 activity |
TW200720289A (en) | 2005-04-01 | 2007-06-01 | Hoffmann La Roche | Antibodies against CCR5 and uses thereof |
CA2607697C (en) | 2005-05-10 | 2015-01-06 | Biogen Idec Ma Inc. | Treating and evaluating inflammatory disorders |
WO2006130429A2 (en) | 2005-05-27 | 2006-12-07 | Biogen Idec Ma Inc. | Treatment of cancer |
HUE030701T2 (hu) | 2005-05-27 | 2017-05-29 | Biogen Ma Inc | Tweak-kötõ antitestek |
JP2008546647A (ja) | 2005-06-08 | 2008-12-25 | デューク ユニバーシティ | 移植のための抗−cd19抗体治療 |
KR20080032097A (ko) | 2005-06-20 | 2008-04-14 | 메다렉스, 인코포레이티드 | 씨디19 항체 및 그의 용도 |
US20070041979A1 (en) | 2005-08-19 | 2007-02-22 | Raju T S | Proteolysis resistant antibody preparations |
PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
WO2008057634A2 (en) | 2006-10-26 | 2008-05-15 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
DE102005060813A1 (de) | 2005-12-20 | 2007-06-28 | Rheinisch-Westfälische Technische Hochschule Aachen | Selektive Markierung der Glykane von Antikörpern mit modifizierten Nukleotidzuckern als Substrate von rekombinanten Galactosyltransferasen |
EP1878747A1 (en) | 2006-07-11 | 2008-01-16 | greenovation Biotech GmbH | Glyco-engineered antibodies |
US8093006B2 (en) | 2009-04-02 | 2012-01-10 | Hoffmann-La Roche Inc. | Antibodies against human tweak and uses thereof |
-
2011
- 2011-09-30 KR KR1020137011352A patent/KR101584416B1/ko not_active IP Right Cessation
- 2011-09-30 US US13/250,485 patent/US9187564B2/en not_active Expired - Fee Related
- 2011-09-30 PE PE2013000786A patent/PE20131411A1/es not_active Application Discontinuation
- 2011-09-30 BR BR112013007293A patent/BR112013007293A2/pt not_active IP Right Cessation
- 2011-09-30 SG SG2013020318A patent/SG188605A1/en unknown
- 2011-09-30 CN CN201180047922.2A patent/CN103154029B/zh not_active Expired - Fee Related
- 2011-09-30 MX MX2013003592A patent/MX343114B/es active IP Right Grant
- 2011-09-30 EP EP11766965.5A patent/EP2625200A1/en not_active Withdrawn
- 2011-09-30 CA CA2809632A patent/CA2809632A1/en not_active Abandoned
- 2011-09-30 AU AU2011311673A patent/AU2011311673B2/en not_active Ceased
- 2011-09-30 JP JP2013532140A patent/JP5941049B2/ja not_active Expired - Fee Related
- 2011-09-30 WO PCT/EP2011/067070 patent/WO2012045671A1/en active Application Filing
- 2011-09-30 EA EA201300418A patent/EA201300418A1/ru unknown
- 2011-10-03 AR ARP110103661A patent/AR083336A1/es unknown
- 2011-10-04 TW TW100135935A patent/TWI482630B/zh not_active IP Right Cessation
-
2012
- 2012-12-24 NZ NZ607588A patent/NZ607588A/en not_active IP Right Cessation
-
2013
- 2013-03-12 CR CR20130108A patent/CR20130108A/es unknown
- 2013-04-04 EC ECSP13012542 patent/ECSP13012542A/es unknown
- 2013-04-04 CL CL2013000901A patent/CL2013000901A1/es unknown
- 2013-05-03 MA MA35867A patent/MA34642B1/fr unknown
- 2013-12-10 HK HK13113725.0A patent/HK1186195A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
SG188605A1 (en) | 2013-04-30 |
EP2625200A1 (en) | 2013-08-14 |
PE20131411A1 (es) | 2013-12-16 |
WO2012045671A1 (en) | 2012-04-12 |
US20120121583A1 (en) | 2012-05-17 |
KR101584416B1 (ko) | 2016-01-13 |
NZ607588A (en) | 2014-02-28 |
TWI482630B (zh) | 2015-05-01 |
AR083336A1 (es) | 2013-02-21 |
JP5941049B2 (ja) | 2016-06-29 |
BR112013007293A2 (pt) | 2016-06-14 |
AU2011311673B2 (en) | 2015-09-17 |
CN103154029A (zh) | 2013-06-12 |
JP2013543383A (ja) | 2013-12-05 |
CR20130108A (es) | 2013-04-29 |
MX2013003592A (es) | 2013-05-31 |
AU2011311673A1 (en) | 2013-03-14 |
MA34642B1 (fr) | 2013-11-02 |
EA201300418A1 (ru) | 2013-09-30 |
ECSP13012542A (es) | 2013-06-28 |
US9187564B2 (en) | 2015-11-17 |
HK1186195A1 (zh) | 2014-03-07 |
TW201219054A (en) | 2012-05-16 |
CN103154029B (zh) | 2015-11-25 |
CL2013000901A1 (es) | 2013-11-29 |
CA2809632A1 (en) | 2012-04-12 |
KR20130062369A (ko) | 2013-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX343114B (es) | Anticuerpos contra la tweak humana y usos de los mismos. | |
WO2010017103A3 (en) | Fully human anti-human nkg2d monoclonal antibodies | |
TN2015000348A1 (en) | Antibodies that bind il-23 | |
TN2009000383A1 (en) | Anti - sclerostin antibodies | |
NZ600622A (en) | Compositions and methods for antibodies targeting complement protein c5 | |
NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
WO2011119979A3 (en) | Antibodies to muc16 and methods of use thereof | |
NZ599875A (en) | Human il-23 antigen binding proteins | |
NZ595235A (en) | Compositions and methods for increasing muscle growth | |
MY161724A (en) | Therapeutic canine immunoglobulins and methods of using the same | |
WO2008030706A3 (en) | Anti-myostatin antibodies | |
TN2011000528A1 (en) | Compositions and methods for antibodies targeting complement protein c3b | |
WO2011094259A3 (en) | Cd127 binding proteins | |
EA201291067A1 (ru) | Гуманизированные антигенсвязывающие белки к миостатину | |
EA201201227A1 (ru) | Бипаратопные а-бета-связывающие полипептиды | |
WO2009013543A3 (en) | Targeted binging agents directed to kdr and uses thereof - 035 | |
UA105520C2 (uk) | Антитіла до людського tweak та їхнє застосування | |
WO2012156532A8 (en) | Anti-human-her3 antibodies and uses thereof | |
WO2009000929A3 (en) | Composition and method for treatment of autoimmune disease | |
WO2011092593A3 (en) | Hiv-1 neutralizing antibodies and uses thereof | |
MY163133A (en) | Humanized il-25 antibodies | |
MY170404A (en) | Antigen binding proteins | |
WO2011116212A3 (en) | Bone morphogenetic protein receptor binding agents and methods of their use | |
IN2012DN01981A (es) | ||
CO6680666A2 (es) | Anticuerpos contra la tweak humana y usos de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |